Granules India | Business Upturn

Latest Articles

Granules India

Granules India subsidiary receives FDA Tentative Approval for Generic Amphetamine Extended-Release Orally Disintegrating Tablets

Corporates · Dec 22, 2025

Granules India

Granules India subsidiary receives five procedural observations after US FDA GMP inspection

Corporates · Dec 19, 2025

Granules India

Granules India subsidiary secures FDA EIR for Hyderabad Facility

Corporates · Dec 12, 2025

Granules India

Granules India Q2 Results: Revenue jumps 34.2% YoY to Rs 1,297 crore, net profit up 35%

Quarterly Results · Nov 13, 2025

Granules India

Granules India’s Hyderabad unit gets first U.S. FDA approval

Corporates · Nov 11, 2025

Granules India

Granules India receives EIR from US FDA for its Virginia facility

Corporates · Nov 5, 2025

Granules India

Granules India receives US FDA EIR with VAI classification for Bonthapally API facility

Corporates · Oct 29, 2025

Granules India

Granules India Q1 Results: Revenue jumps 2.56% YoY to Rs 1,210.11 crore, net profit falls 16.37% YoY

Quarterly Results · Aug 12, 2025

Granules India

Granules India’s Hyderabad unit receives one US FDA observation after Pre-Approval Inspection

Corporates · Aug 1, 2025

Granules India

Granules India clears US FDA Pre-Approval Inspection with zero observations

Corporates · Jun 28, 2025

Granules India

Granules India shares drop 3.6% after receiving US FDA warning letter for Gagillapur facility

Stock Market · Feb 28, 2025

Granules India

Granules India receives US FDA warning letter for Gagillapur facility

Corporates · Feb 27, 2025

Granules India

Granules India shares fall nearly 4% on Q3 results

Stock Market · Jan 24, 2025

By Aditya Bhagchandani

Granules India

Granules India Q3 FY25 Results: Net Profit down 6.4% YoY to Rs 117.6 crore

Corporates · Jan 24, 2025

By Aditya Bhagchandani

Granules India

Granules India receives USFDA approval for Lisdexamfetamine Dimesylate Chewable tablets

Corporates · Dec 17, 2024

Showing 15 of 25 articles